ArticleJournal of medicinal chemistry2025
Novel Optical Imaging Probe for the Targeted Visualization of NLRP3 Inflammasomes in Living Retina.
Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Activation of the NLR-family pyrin domain-containing 3 (NLRP3) inflammasome has been associated with diabetic retinopathy progression. We have synthesized a highly sensitive molecular imaging probe, InflammaProbe-2, as an early detection diagnostic tool for the in vivo molecular imaging of NLRP3 inflammasomes in living diabetic retina. The ability of InflammaProbe-2 for the targeted visualization of the NLRP3 inflammasome was assessed using an enzyme-linked immunosorbent assay (ELISA) by comparing its ability to inhibit the NLRP3-mediated secretion of IL-1β. InflammaProbe-2 was able to visualize NLRP3 inflammasomes in ARPE-19 cells treated under hyperglycemia as well as inflammatory conditions. Furthermore, InflammaProbe-2-dependent in vivo and ex vivo imaging of the NLRP3 inflammasome was achieved via fluorescence enhancement in streptozotocin (STZ)-induced diabetic retinopathy. In addition, the toxicity of InflammaProbe-2 was assessed in vitro and in vivo studies. InflammaProbe-2 showed no significant changes in the a-wave and b-wave amplitudes of their electrical response to flashes of light.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.